Literature DB >> 9255115

Measurement of the quality of life in rheumatic disorders using the EuroQol.

F Wolfe1, D J Hawley.   

Abstract

The EuroQol is a validated quality of life (QOL) scale that has been used in population and clinical studies, and has been reported in patients with rheumatoid arthritis (RA). It is short, simple to complete, and might be suitable for surveys of rheumatic disease patients. The properties of this instrument were investigated in a postal survey of 1372 rheumatic disease patients, including 537 with RA, 319 with osteoarthritis (OA) and 516 with fibromyalgia. In addition, simultaneous measurements of functional disability, pain, psychological status, global severity and demographic characteristics were made. EuroQol scores (0.57) were significantly lower than VAS health state scores (0.67) and arthritis-related global severity scores (0.62). QOL was similar in RA and OA, but lower in fibromyalgia, across all instruments. The distribution of EuroQol scores had many gaps and was not continuous. EuroQol did not reflect VAS QOL scores at EuroQol levels below 0.5, and the mean score difference between the instruments below that level was 0.43. Many patients with low EuroQol scores (including some with health states that were 'worse than death') had high VAS scores. These differences appear to have arisen because disability, pain and depression questions ask about mild or moderate problems, but not both, thereby forcing scale compression in the mid ranges. In addition, the 'severe' value is so extremely abnormal that few patients endorse it. Finally, penalty scores are applied to those with at least one maximally abnormal score. The scoring properties and distributional aspects of the EuroQol indicate substantial problems in its use in rheumatic disease patients.

Entities:  

Mesh:

Year:  1997        PMID: 9255115     DOI: 10.1093/rheumatology/36.7.786

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  30 in total

1.  Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy.

Authors:  B Conner-Spady; C Cumming; J M Nabholtz; P Jacobs; D Stewart
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

2.  Validity and reliability of the EQ-5D self-report questionnaire in English-speaking Asian patients with rheumatic diseases in Singapore.

Authors:  N Luo; L H Chew; K Y Fong; D R Koh; S C Ng; K H Yoon; S Vasoo; S C Li; J Thumboo
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

3.  Measuring health-related quality of life in Kashin-Beck disease using EQ-5D.

Authors:  Umer Farooq; Xiong Guo; Ling-Hsiang Chuang; Hua Fang; Guihua Zhuang; Chuantao Xia
Journal:  Qual Life Res       Date:  2010-12-24       Impact factor: 4.147

4.  The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA.

Authors:  Xuejing Jin; Fatima Al Sayah; Arto Ohinmaa; Deborah A Marshall; Christopher Smith; Jeffrey A Johnson
Journal:  Clin Orthop Relat Res       Date:  2019-07       Impact factor: 4.176

5.  The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension.

Authors:  S P McKenna; N Doughty; D M Meads; L C Doward; J Pepke-Zaba
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

6.  Comparing the validity and responsiveness of the EQ-5D-5L to the Oxford hip and knee scores and SF-12 in osteoarthritis patients 1 year following total joint replacement.

Authors:  Barbara L Conner-Spady; Deborah A Marshall; Eric Bohm; Michael J Dunbar; Tom W Noseworthy
Journal:  Qual Life Res       Date:  2018-02-08       Impact factor: 4.147

7.  The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.

Authors:  M J Harrison; L M Davies; N J Bansback; M J McCoy; S M M Verstappen; K Watson; D P M Symmons
Journal:  Qual Life Res       Date:  2009-09-24       Impact factor: 4.147

Review 8.  A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.

Authors:  Hirsch S Ruchlin; Ralph P Insinga
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  Supervised and non-supervised Nordic walking in the treatment of chronic low back pain: a single blind randomized clinical trial.

Authors:  Jan Hartvigsen; Lars Morsø; Tom Bendix; Claus Manniche
Journal:  BMC Musculoskelet Disord       Date:  2010-02-10       Impact factor: 2.362

10.  Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study.

Authors:  H S J Picavet; N Hoeymans
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.